SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

October 20, 2024

Study Completion Date

December 30, 2024

Conditions
EGFR Positive Non-small Cell Lung Cancer
Interventions
DRUG

SMET12

"1. platinum-containing two-drug chemotherapy:Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV=5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg,Q2W;~3. SMET12: IV,60μg,Q2W,injected the day after toripalimab ;"

DRUG

SMET12

"1. platinum-containing two-drug chemotherapy:Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1,d8,d15;~2. Toripalimab, IV, 3mg/kg,Q2W;~3. SMET12: IV,60μg,Q2W,injected the day after toripalimab ;"

DRUG

SMET12

"1. chemotherapy:Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg,Q2W;~3. SMET12: IV,60μg,Q2W,injected the day after toripalimab ;"

Trial Locations (1)

Unknown

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT06208033 - SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter